<!DOCTYPE html PUBLIC "-">
<html xmlns:v="http://validator.pragmaticdata.com/result" xmlns:str="http://exslt.org/strings">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta name="documentId" content="6815251d-7f8d-4b04-8fc5-b1ec85a617ca">
<meta name="documentSetId" content="04cc9ef7-c02a-4e92-a655-0062674e8487">
<meta name="documentVersionNumber" content="6">
<meta name="documentEffectiveTime" content="20231031">
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no, minimum-scale=1.0, maximum-scale=1.0">
<meta name="apple-mobile-web-app-capable" content="yes">
<title>These highlights do not include all the information needed to use VABYSMO safely and effectively. See full prescribing information for VABYSMO. VABYSMO® (faricimab-svoa) injection, for intravitreal use Initial U.S. Approval:  2022</title>
<link rel="stylesheet" type="text/css" href="../core/spl.css">
<link rel="stylesheet" type="text/css" href="../assets/css/styles.css">
<link rel="stylesheet" type="text/css" href="../assets/css/product.css">
<link rel="stylesheet" type="text/css" href="product.css">
<script src="../assets/js/jquery.min.js"></script><script type="text/javascript" src="../assets/js/jquery.kinetic.js"></script><script type="text/javascript" src="../assets/js/ipi.js"></script><script src="../core/spl.js" type="text/javascript" charset="utf-8">/* */</script><style>
					/**/
					#pi-content #scrollable {
						overflow: scroll;
						-webkit-overflow-scrolling:touch;
						left: 0px;
					}
					
					#nav #scrollable {
						overflow: scroll;
						-webkit-overflow-scrolling:touch;
					}
					
					body {padding:0; margin:0;}
					.ipad {width:1024px; height:768px; background-image:url(heme_bkg.jpg);}
					.backBtn {margin-top:-2px;}
					.searchMin {margin-top:-2px;}
					nav {float:left; width:300px; height:700px; overflow:hidden;}
					nav div {width:295px; height:680px; overflow:scroll;}
					nav div ul {width:255px;}
					
					div.c9 {font-size: 11px; text-align: center}
					div.c8 {float: left; height: 700px; overflow: hidden; width: 724px}
					col.c7 {text-align: left}
					col.c6 {text-align: center}
					li.c3 {border-top-right-radius: 10px !important; border-bottom-right-radius: 10px !important; cursor:hand}
					a.c2 {display:none}
					
					footer {margin-top:40px; clear:both; float:left; width:100%}
					footer div {font-size:11px text-align: center}
					/**/
				</style>
</head>
<body class="spl" id="spl" onload="window.focus();"><div class="ipad">
<div class="backBtn"><div id="backButton" onclick="backToTop();"><img src="../assets/images/bck_top.png"></div></div>
<header id="searchForm" class="searchMin"><input type="text" id="searchBox" autocapitalize="off" autocorrect="off" autocomplete="off" value="Search" onfocus="sFocus(this)"><span id="searchParams"><span id="count"></span><div id="searchBtn" class="searchBtnHeme" onClick="runSearch();"><img src="../assets/images/heme_search-btn.png"></div>
<a id="next" style="display:none" class="newNext"><img src="../assets/images/next.png" height="42" width="42"></a></span></header><div class="clear"></div>
<div id="Index" class="Index"><nav id="nav" role="navigation"><div id="scrollable"><ul class="top">
<a href="#Highlights" class="toc"><h1>HIGHLIGHTS</h1></a><a href="#section-S1"><h1>1 INDICATIONS AND USAGE</h1></a><a href="#section-S2"><h1>2 DOSAGE AND ADMINISTRATION</h1></a><a href="#section-S2.1"><h2>2.1	General Dosing Information</h2></a><a href="#section-S2.2"><h2>2.2	Neovascular (wet) Age-Related Macular Degeneration (nAMD)</h2></a><a href="#section-S2.3"><h2>2.3	Diabetic Macular Edema (DME)</h2></a><a href="#section-S2.4"><h2>2.4     Macular Edema Following Retinal Vein Occlusion (RVO) </h2></a><a href="#section-S2.5"><h2>2.5	Preparation for Administration</h2></a><a href="#section-S2.6"><h2>2.6	Injection Procedure</h2></a><a href="#section-S3"><h1>3 DOSAGE FORMS AND STRENGTHS</h1></a><a href="#section-S4"><h1>4 CONTRAINDICATIONS</h1></a><a href="#section-S4.1"><h2>4.1	Ocular or Periocular Infections</h2></a><a href="#section-S4.2"><h2>4.2	Active Intraocular Inflammation</h2></a><a href="#section-S4.3"><h2>4.3	Hypersensitivity</h2></a><a href="#section-S5"><h1>5 WARNINGS AND PRECAUTIONS</h1></a><a href="#section-S5.1"><h2>5.1	Endophthalmitis and Retinal Detachments</h2></a><a href="#section-S5.2"><h2>5.2	Increase in Intraocular Pressure</h2></a><a href="#section-S5.3"><h2>5.3	Thromboembolic Events</h2></a><a href="#section-S5.4"><h2>5.4	Retinal Vasculitis and/or Retinal Vascular Occlusion </h2></a><a href="#section-S6"><h1>6 ADVERSE REACTIONS</h1></a><a href="#section-S6.1"><h2>6.1 	Clinical Trials Experience</h2></a><a href="#section-S6.2"><h2>6.2 Postmarketing Experience</h2></a><a href="#section-S8"><h1>8 USE IN SPECIFIC POPULATIONS</h1></a><a href="#section-S8.1"><h2>8.1 Pregnancy</h2></a><a href="#section-S8.2a"><h2>8.2 Lactation</h2></a><a href="#section-S8.3a"><h2>8.3	Females and Males of Reproductive Potential</h2></a><a href="#section-S8.4"><h2>8.4	Pediatric Use</h2></a><a href="#section-S8.5"><h2>8.5 Geriatric Use</h2></a><a href="#section-S11"><h1>11 DESCRIPTION</h1></a><a href="#section-S12"><h1>12 CLINICAL PHARMACOLOGY</h1></a><a href="#section-S12.1"><h2>12.1	Mechanism of Action</h2></a><a href="#section-S12.2"><h2>12.2 Pharmacodynamics</h2></a><a href="#section-S12.3"><h2>12.3 Pharmacokinetics</h2></a><a href="#section-S12.6"><h2>12.6	Immunogenicity</h2></a><a href="#section-S13"><h1>13 NONCLINICAL TOXICOLOGY</h1></a><a href="#section-S13.1"><h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2></a><a href="#section-S14"><h1>14 CLINICAL STUDIES</h1></a><a href="#section-S14.1"><h2>14.1	Neovascular (wet) Age-Related Macular Degeneration (nAMD)</h2></a><a href="#section-S14.2"><h2>14.2	Diabetic Macular Edema (DME)</h2></a><a href="#section-S14.3"><h2>14.3	Macular Edema Following Retinal Vein Occlusion (RVO) </h2></a><a href="#section-S16"><h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1></a><a href="#section-S16.1"><h2>16.1	How Supplied</h2></a><a href="#section-S16.2"><h2>16.2	Storage and Handling</h2></a><a href="#section-S17"><h1>17	PATIENT COUNSELING INFORMATION</h1></a><a href="#section-"><h1>PRINCIPAL DISPLAY PANEL - 6 mg Vial Carton</h1></a>
</ul></div></nav></div>
<div id="pi-content" class="Contents" style="float:left; width:724px; height:700px; overflow:hidden;"><div style="float:left; width:724px; height:700px; overflow:scroll">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div id="Highlights" name="Highlights" class="Highlights"><table cellspacing="5" cellpadding="20" width="100%" style="table-layout:fixed"><tr><td width="50%" align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VABYSMO safely and effectively. See full prescribing information for VABYSMO.<br><br> VABYSMO<span class="Sup">®</span> (faricimab-svoa) injection, for intravitreal use<br> Initial U.S. Approval:  2022</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%" class="Noautorules">
<col width="90%" align="left" valign="top">
<col width="10%" align="right" valign="top">
<tbody class="Headless">
<tr>
<td align="left">Indications and Usage, Macular Edema Following Retinal Vein Occlusion (RVO) (<a href="#section-S1.3">1.3</a>)</td>
<td align="right">10/2023</td>
</tr>
<tr>
<td align="left">Dosage and Administration, Diabetic Macular Edema (<a href="#section-S2.3">2.3</a>)</td>
<td align="right">1/2023</td>
</tr>
<tr>
<td align="left">Dosage and Administration, Macular Edema Following Retinal Vein Occlusion (<a href="#section-S2.4">2.4</a>)</td>
<td align="right">10/2023</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, Retinal Vasculitis and/or Retinal Vascular Occlusion (<a href="#section-S5.4">5.4</a>)</td>
<td align="right">10/2023</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlights">VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: </p>
<ul class="Disc">
<li>Neovascular (Wet) Age-Related Macular Degeneration (nAMD) (<a href="#section-S1.1">1.1</a>)</li>
<li>Diabetic Macular Edema (DME) (<a href="#section-S1.2">1.2</a>)</li>
<li>Macular Edema Following Retinal Vein Occlusion (RVO) (<a href="#section-S1.3">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlights">For intravitreal injection. (<a href="#section-S2.1">2.1</a>) </p>
<ul class="Disc">
<li>
<span class="Underline">Neovascular (Wet) Age-Related Macular Degeneration (nAMD)</span><ul class="Circle"><li>The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to give a 6 mg dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36 and 48; or 3) Weeks 20, 28, 36 and 44. Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly. (<a href="#section-S2.2">2.2</a>)</li></ul>
</li>
<li>D<span class="Underline">iabetic Macular Edema (DME)</span><ul class="Circle"><li>VABYSMO is recommended to be dosed by following one of these two dose regimens: 1) 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days ± 7 days, monthly) for at least 4 doses. If after at least 4 doses, resolution of edema based on the central subfield thickness (CST) of the macula as measured by optical coherence tomography is achieved, then the interval of dosing may be modified by extensions of up to 4 week interval increments or reductions of up to 8 week interval increments based on CST and visual acuity evaluations; or 2) 6 mg dose of VABYSMO can be administered every 4 weeks for the first 6 doses, followed by 6 mg dose via intravitreal injection at intervals of every 8 weeks (2 months). Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly. (<a href="#section-S2.3">2.3</a>)</li></ul>
</li>
<li>
<span class="Underline">Macular Edema Following Retinal Vein Occlusion (RVO) </span><ul class="Circle"><li>The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for 6 months. (<a href="#section-S2.4">2.4</a>)</li></ul>
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlights">Injection: 120 mg/mL solution in a single-dose vial (<a href="#section-S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Ocular or periocular infection (<a href="#section-S4.1">4.1</a>)</li>
<li>Active intraocular inflammation (<a href="#section-S4.2">4.2</a>)</li>
<li>Hypersensitivity (<a href="#section-S4.3">4.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management. (<a href="#section-S5.1">5.1</a>)</li>
<li>Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. (<a href="#section-S5.2">5.2</a>)</li>
<li>There is a potential risk of arterial thromboembolic events (ATEs) associated with VEGF inhibition. (<a href="#section-S5.3">5.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlights">The most common adverse reactions (≥ 5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%). (<a href="#section-S6.1">6.1</a>) </p>
<br><p class="Highlights"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div><div></div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2023</p>
</div></td></tr></table></div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-S1" id="section-S1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S1.1" id="section-S1.1"></a><p></p>
<h2>1.1	Neovascular (wet) Age-Related Macular Degeneration (nAMD)</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S1.2" id="section-S1.2"></a><p></p>
<h2>1.2	Diabetic Macular Edema (DME)</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S1.3" id="section-S1.3"></a><p></p>
<h2>1.3     Macular Edema Following Retinal Vein Occlusion (RVO)</h2>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-S2" id="section-S2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S2.1" id="section-S2.1"></a><p></p>
<h2>2.1	General Dosing Information</h2>
<p class="First">For intravitreal injection. VABYSMO must be administered by a qualified physician. Each vial should only be used for the treatment of a single eye.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S2.2" id="section-S2.2"></a><p></p>
<h2>2.2	Neovascular (wet) Age-Related Macular Degeneration (nAMD)</h2>
<p class="First">The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to give a 6 mg dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36 and 48; or 3) Weeks 20, 28, 36 and 44. Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S2.3" id="section-S2.3"></a><p></p>
<h2>2.3	Diabetic Macular Edema (DME)</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">VABYSMO is recommended to be dosed by following one of these two dose regimens: 1) 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days ± 7 days, monthly) for at least 4 doses. If after at least 4 doses, resolution of edema based on the central subfield thickness (CST) of the macula as measured by optical coherence tomography is achieved, then the interval of dosing may be modified by extensions of up to 4 week interval increments or reductions of up to 8 week interval increments based on CST and visual acuity evaluations; or  2) 6 mg dose of VABYSMO can be administered every 4 weeks for the first 6 doses, followed by 6 mg dose via intravitreal injection at intervals of every 8 weeks (2 months). Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S2.4" id="section-S2.4"></a><p></p>
<h2>2.4     Macular Edema Following Retinal Vein Occlusion (RVO) </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for 6 months.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S2.5" id="section-S2.5"></a><p></p>
<h2>2.5	Preparation for Administration</h2>
<table width="100%" class="Noautorules">
<col width="50%" align="left" valign="top">
<col width="50%" align="left" valign="top">
<tbody class="Headless">
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>1.</dt>
<dd> Before you start:</dd>
</dl></td></tr>
<tr class="Botrule"><td class="Toprule" align="left" colspan="2"><ul class="Disc">
<li>Read all the instructions carefully before using VABYSMO.</li>
<li>The VABYSMO kit includes a glass vial and transfer filter needle. The glass vial is for a single dose only. The filter needle is for single use only.</li>
<li>VABYSMO should be stored refrigerated at temperatures between 2ºC to 8ºC (36ºF to 46ºF). <span class="Bold">Do not</span> freeze. <span class="Bold">Do not</span> shake.</li>
<li>Allow VABYSMO to reach room temperature, 20°C to 25°C (68°F to 77°F) before proceeding with the administration. The VABYSMO vial may be kept at room temperature for up to 24 hours.  Keep the vial in the original carton to protect from light.</li>
<li>VABYSMO should be inspected visually for particulate matter and discoloration prior to administration. VABYSMO is a clear to opalescent and colorless to brownish-yellow liquid solution.<br><span class="Bold">Do not</span> use if particulates, cloudiness, or discoloration are visible.<br><span class="Bold">Do not</span> use if the packaging, vial and/or transfer filter needle are expired, damaged, or have been tampered with (see <span class="Bold"><a href="#section-FIGURE_A">Figure A</a></span>).</li>
<li>Use aseptic technique to carry out the preparation of the intravitreal injection.</li>
</ul></td></tr>
<tr class="Botrule"><td align="center" colspan="2">
<a name="FIGURE_A"></a><img alt="Figure A" src="faricimab-01.jpg"><br> Figure A</td></tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>2.</dt>
<dd>Gather the following supplies:<ul class="Disc">
<li>One VABYSMO vial (included)</li>
<li>One sterile 5-micron blunt transfer filter needle 18-gauge × 1½ inch (included)</li>
<li>One sterile 1 mL Luer lock syringe with a 0.05 mL dose mark (<span class="Bold">not included</span>)</li>
<li>One sterile injection needle 30-gauge × ½ inch (<span class="Bold">not included</span>)<dl>
<dt> </dt>
<dd>
<span class="Bold">Note</span> that a 30-gauge injection needle is recommended to avoid increased injection forces that could be experienced with smaller diameter needles.</dd>
</dl>
</li>
<li>Alcohol swab (<span class="Bold">not included</span>).</li>
</ul>
</dd>
</dl></td></tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>3.</dt>
<dd> To ensure all liquid settles at the bottom of the vial, place the vial upright on a flat surface (for about 1 minute) after removal from packaging (see <a href="#section-FIGURE_B">Figure B</a>). Gently tap the vial with your finger (see <a href="#section-FIGURE_C">Figure C</a>), as liquid may stick to the top of the vial.</dd>
</dl></td></tr>
<tr class="Botrule">
<td align="center">
<a name="FIGURE_B"></a><img alt="Figure B" src="faricimab-02.jpg"><br> Figure B</td>
<td align="center">
<a name="FIGURE_C"></a><img alt="Figure C" src="faricimab-03.jpg"><br> Figure C</td>
</tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>4.</dt>
<dd> Remove the flip-off cap from the vial (see <span class="Bold"><a href="#section-FIGURE_D">Figure D</a></span>) and wipe the vial septum with an alcohol swab (see <span class="Bold"><a href="#section-FIGURE_E">Figure E</a></span>).</dd>
</dl></td></tr>
<tr class="Botrule">
<td align="center">
<a name="FIGURE_D"></a><img alt="Figure D" src="faricimab-04.jpg"><br> Figure D</td>
<td align="center">
<a name="FIGURE_E"></a><img alt="Figure E" src="faricimab-05.jpg"><br> Figure E</td>
</tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>5.</dt>
<dd> Aseptically and firmly attach the included 18-gauge × 1½ inch transfer filter needle onto a 1 mL Luer lock syringe (see <span class="Bold"><a href="#section-FIGURE_F">Figure F</a></span>).</dd>
</dl></td></tr>
<tr class="Botrule"><td align="center" colspan="2">
<a name="FIGURE_F"></a><img alt="Figure F" src="faricimab-06.jpg"><br> Figure F</td></tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>6.</dt>
<dd> Using aseptic technique, push the transfer filter needle into the center of the vial septum (see <span class="Bold"><a href="#section-FIGURE_G">Figure G</a></span>), push it all the way in, then tilt the vial slightly so that the needle touches the bottom edge of the vial (see <span class="Bold"><a href="#section-FIGURE_H">Figure H</a></span>).</dd>
</dl></td></tr>
<tr class="Botrule">
<td align="center">
<a name="FIGURE_G"></a><img alt="Figure G" src="faricimab-07.jpg"><br> Figure G</td>
<td align="center">
<a name="FIGURE_H"></a><img alt="Figure H" src="faricimab-08.jpg"><br> Figure H</td>
</tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>7.</dt>
<dd> Hold the vial slightly inclined and <span class="Bold">slowly</span> withdraw all the liquid from the vial (see <span class="Bold"><a href="#section-FIGURE_I">Figure I</a></span>). Keep the bevel of the transfer filter needle submerged in the liquid, to avoid introduction of air.</dd>
</dl></td></tr>
<tr class="Botrule"><td align="center" colspan="2">
<a name="FIGURE_I"></a><img alt="Figure I" src="faricimab-09.jpg"><br> Figure I</td></tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>8.</dt>
<dd> Ensure that the plunger rod is drawn sufficiently back when emptying the vial, in order to completely empty the transfer filter needle (see <span class="Bold"><a href="#section-FIGURE_I">Figure I</a></span>).</dd>
</dl></td></tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>9.</dt>
<dd> Disconnect the transfer filter needle from the syringe and dispose of it in accordance with local regulations.<dl>
<dt> </dt>
<dd><span class="Bold">Do not use the transfer filter needle for the intravitreal injection.</span></dd>
</dl>
</dd>
</dl></td></tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>10.</dt>
<dd> Aseptically and firmly attach a 30-gauge × ½ inch injection needle onto the Luer lock syringe (see <span class="Bold"><a href="#section-FIGURE_J">Figure J</a></span>).</dd>
</dl></td></tr>
<tr class="Botrule"><td align="center" colspan="2">
<a name="FIGURE_J"></a><img alt="Figure J" src="faricimab-10.jpg"><br> Figure J</td></tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>11.</dt>
<dd> Carefully remove the plastic needle shield from the needle by pulling it straight off.</dd>
</dl></td></tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>12.</dt>
<dd> To check for air bubbles, hold the syringe with the needle pointing up. If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see <span class="Bold"><a href="#section-FIGURE_K">Figure K</a></span>).</dd>
</dl></td></tr>
<tr class="Botrule"><td align="center" colspan="2">
<a name="FIGURE_K"></a><img alt="Figure K" src="faricimab-11.jpg"><br> Figure K</td></tr>
<tr class="Botrule"><td align="left" colspan="2"><dl class="Arabic">
<dt>13.</dt>
<dd> Carefully expel the air from the syringe and needle, and <span class="Bold">slowly</span> depress the plunger to align the rubber stopper tip to the 0.05 mL dose mark. The syringe is ready for the injection (see <span class="Bold"><a href="#section-FIGURE_L">Figure L</a></span>). Ensure that the injection is given <span class="Bold">immediately</span> after preparation of the dose.</dd>
</dl></td></tr>
<tr class="Botrule"><td align="center" colspan="2">
<a name="FIGURE_L"></a><img alt="Figure L" src="faricimab-12.jpg"><br> Figure L</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S2.6" id="section-S2.6"></a><p></p>
<h2>2.6	Injection Procedure</h2>
<p class="First">The intravitreal injection procedure must be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent), and the availability of sterile paracentesis equipment (if required). Adequate anesthesia and a broad-spectrum microbicide should be administered prior to the injection. Inject slowly until the rubber stopper reaches the end of the syringe to deliver the volume of 0.05 mL. Confirm delivery of the full dose by checking that the rubber stopper has reached the end of the syringe barrel.</p>
<p>Any unused medicinal product or waste material should be disposed of in accordance with local regulations.</p>
<p>Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available. Following intravitreal injection, patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment (e.g., vision loss, eye pain, redness of the eye, photophobia, blurring of vision) without delay <span class="Italics">[see <a href="#section-S17">Patient Counseling Information (17)</a>]</span>. Each syringe should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new syringe should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before VABYSMO is administered to the other eye.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-S3" id="section-S3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Injection: 120 mg/mL clear to opalescent, colorless to brownish-yellow solution in a single-dose vial.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-S4" id="section-S4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S4.1" id="section-S4.1"></a><p></p>
<h2>4.1	Ocular or Periocular Infections</h2>
<p class="First">VABYSMO is contraindicated in patients with ocular or periocular infections.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S4.2" id="section-S4.2"></a><p></p>
<h2>4.2	Active Intraocular Inflammation</h2>
<p class="First">VABYSMO is contraindicated in patients with active intraocular inflammation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S4.3" id="section-S4.3"></a><p></p>
<h2>4.3	Hypersensitivity</h2>
<p class="First">VABYSMO is contraindicated in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-S5" id="section-S5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S5.1" id="section-S5.1"></a><p></p>
<h2>5.1	Endophthalmitis and Retinal Detachments</h2>
<p class="First">Intravitreal injections, including Vabysmo, have been associated with endophthalmitis and retinal detachments <span class="Italics">[see <a href="#section-S6.1">Adverse Reactions (6.1)</a>]</span>. Proper aseptic injection techniques must always be used when administering VABYSMO. Patients should be instructed to report any signs or symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management <span class="Italics">[see <a href="#section-S2.6">Dosage and Administration (2.6)</a> and <a href="#section-S17">Patient Counseling Information (17)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S5.2" id="section-S5.2"></a><p></p>
<h2>5.2	Increase in Intraocular Pressure</h2>
<p class="First">Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of intravitreal injection, including with VABYSMO <span class="Italics">[see <a href="#section-S6.1">Adverse Reactions (6.1)</a>].</span> IOP and the perfusion of the optic nerve head should be monitored and managed appropriately <span class="Italics">[see <a href="#section-S2.6">Dosage and Administration (2.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S5.3" id="section-S5.3"></a><p></p>
<h2>5.3	Thromboembolic Events</h2>
<p class="First">Although there was a low rate of arterial thromboembolic events (ATEs) observed in the VABYSMO clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).</p>
<p>The incidence of reported ATEs in the nAMD studies during the first year was 1% (7 out of 664) in patients treated with VABYSMO compared with 1% (6 out of 662) in patients treated with aflibercept <span class="Italics">[see <a href="#section-S14.1">Clinical Studies (14.1)</a>]</span>.</p>
<p>The incidence of reported ATEs in the DME studies from baseline to week 100 was 5% (64 out of 1,262) in patients treated with VABYSMO compared with 5% (32 out of 625) in patients treated with aflibercept <span class="Italics">[see <a href="#section-S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>The incidence of reported ATEs in the RVO studies during the first 6 months was 1.1% (7 out of 641) in patients treated with VABYSMO compared with 1.4% (9 out of 635) in patients treated with aflibercept <span class="Italics">[see <a href="#section-S14.3">Clinical Studies (14.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S5.4" id="section-S5.4"></a><p></p>
<h2>5.4	Retinal Vasculitis and/or Retinal Vascular Occlusion </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of VABYSMO <span class="Italics">[see <a href="#section-S6.2">Adverse Reactions (6.2)</a>]</span>.  Discontinue treatment with VABYSMO in patients who develop these events. Patients should be instructed to report any change in vision without delay.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-S6" id="section-S6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following potentially serious adverse reactions are described elsewhere in the labeling:</p>
<ul class="Disc">
<li>Hypersensitivity <span class="Italics">[see <a href="#section-S4">Contraindications (4)</a>]</span>
</li>
<li>Endophthalmitis and retinal detachments <span class="Italics">[see <a href="#section-S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Increase in intraocular pressure <span class="Italics">[see <a href="#section-S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li>Thromboembolic events <span class="Italics">[see <a href="#section-S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li>Retinal Vasculitis and/or Retinal Vascular Occlusion <span class="Italics">[see <a href="#section-S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="90374-0">
<a name="section-S6.1" id="section-S6.1"></a><p></p>
<h2>6.1 	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to VABYSMO in 2,567 patients, which constituted the safety population in six Phase 3 studies <span class="Italics">[see <a href="#section-S14.1">Clinical Studies (14.1</a>, <a href="#section-S14.2">14.2</a>, <a href="#section-S14.3">14.3)</a>]</span>.</p>
<table width="80%">
<caption><span>Table 1: Common Adverse Reactions (≥ 1%)</span></caption>
<col width="22%" align="left" valign="top">
<col width="13%" align="center" valign="top">
<col width="13%" align="center" valign="top">
<col width="13%" align="center" valign="top">
<col width="13%" align="center" valign="top">
<col width="13%" align="center" valign="top">
<col width="13%" align="center" valign="top">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left">Adverse Reactions</th>
<th class="Rrule" align="center" colspan="3">VABYSMO</th>
<th class="Rrule" align="center" colspan="3">Active Control<br> (aflibercept)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">AMD<br>N=664</th>
<th class="Rrule" align="center">DME<br>N=1,262</th>
<th class="Rrule" align="center">RVO<br>N=641</th>
<th class="Rrule" align="center">AMD<br>N=662</th>
<th class="Rrule" align="center">DME<br>N=625</th>
<th class="Rrule" align="center">RVO<br>N=635</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>AMD only</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Including iridocyclitis, iritis, uveitis, vitritis</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Cataract</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">15%</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">12%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Conjunctival hemorrhage</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Vitreous detachment</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Vitreous floaters</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Retinal pigment epithelial tear<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Intraocular pressure increased</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Eye pain</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Intraocular inflammation<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Eye irritation</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lacrimation increased</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Ocular discomfort</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
</tbody>
</table>
<p>Less common adverse reactions reported in &lt; 1% of the patients treated with VABYSMO were  corneal abrasion, eye pruritus, ocular hyperemia, blurred vision, sensation of foreign body, endophthalmitis, conjunctival hyperaemia, visual acuity reduced, visual acuity reduced transiently, vitreous hemorrhage, retinal tear and rhegmatogenous retinal detachment.</p>
</div>
<div class="Section" data-sectionCode="90375-7">
<a name="section-S6.2" id="section-S6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of VABYSMO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Eye disorders</span>: retinal vasculitis with or without retinal vascular occlusion.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-S8" id="section-S8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-S8.1" id="section-S8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-" id="section-"></a><p></p>
<p class="First"><span class="Underline">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies of VABYSMO administration in pregnant women.</p>
<p>Administration of VABYSMO to pregnant monkeys throughout the period of organogenesis resulted in an increased incidence of abortions at intravenous (IV) doses 158 times the human exposure (based on C<span class="Sub">max</span>) of the maximum recommended human dose <span class="Italics">[see <a href="#section-ANIMAL_DATA">Animal Data</a>]</span>.  Based on the mechanism of action of VEGF and Ang-2 inhibitors, there is a potential risk to female reproductive capacity, and to embryo-fetal development. VABYSMO should not be used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus.</p>
<p>All pregnancies have a background risk of birth defect, loss, and other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2%-4% and of miscarriage is 15%-20% of clinically recognized pregnancies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-" id="section-"></a><p></p>
<p class="First"><span class="Underline">Data</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-ANIMAL_DATA" id="section-ANIMAL_DATA"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>An embryo fetal developmental toxicity study was performed on pregnant cynomolgus monkeys. Pregnant animals received 5 weekly IV injections of VABYSMO starting on day 20 of gestation at 1 or 3 mg/kg. A non-dose dependent increase in pregnancy loss (abortions) was observed at both doses evaluated. Serum exposure (C<span class="Sub">max</span>) in pregnant monkeys at the low dose of 1 mg/kg was 158 times the human exposure at the maximum recommended intravitreal dose of 6 mg once every 4 weeks. A no observed adverse effect level (NOAEL) was not identified in this study.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="77290-5">
<a name="section-S8.2a" id="section-S8.2a"></a><p></p>
<h2>8.2 Lactation</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-" id="section-"></a><p></p>
<p class="First"><span class="Underline">Risk Summary</span></p>
<p>There is no information regarding the presence of faricimab in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Many drugs are transferred in human milk with the potential for absorption and adverse reactions in the breastfed child.</p>
<p>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VABYSMO and any potential adverse effects on the breastfed child from VABYSMO.</p>
</div>
</div>
<div class="Section" data-sectionCode="77291-3">
<a name="section-S8.3a" id="section-S8.3a"></a><p></p>
<h2>8.3	Females and Males of Reproductive Potential</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-" id="section-"></a><p></p>
<p class="First"><span class="Underline">Contraception</span></p>
<p>Females of reproductive potential are advised to use effective contraception prior to the initial dose, during treatment and for at least 3 months following the last dose of VABYSMO.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-" id="section-"></a><p></p>
<p class="First"><span class="Underline">Infertility</span></p>
<p>No studies on the effects of faricimab on human fertility have been conducted and it is not known whether faricimab can affect reproduction capacity. Based on the mechanism of action, treatment with VABYSMO may pose a risk to reproductive capacity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-S8.4" id="section-S8.4"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">The safety and efficacy of VABYSMO in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-S8.5" id="section-S8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In the six clinical studies, approximately 58% (1,496/2,571) of patients randomized to treatment with VABYSMO were ≥ 65 years of age. No significant differences in efficacy or safety of faricimab were seen with increasing age in these studies. No dose adjustment is required in patients 65 years and above.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-S11" id="section-S11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Faricimab-svoa is a humanized bispecific immunoglobulin G1 (IgG1) antibody that binds both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). The fragment crystallizable (Fc) region of faricimab was engineered by selected point mutations to abolish binding interactions with Fcγ and FcRn receptors. Faricimab-svoa has a total molecular weight of approximately 149 kDa and is produced by recombinant DNA technology using mammalian Chinese Hamster Ovary (CHO) cell culture.</p>
<p>VABYSMO (faricimab-svoa) injection is a sterile, clear to opalescent, colorless to brownish-yellow solution in a single-dose glass vial for intravitreal administration. Each single-dose vial is designed to deliver 0.05 mL (50 microliters) of solution containing 6 mg faricimab-svoa, L-histidine (155 mcg), L-methionine (52.2 mcg), polysorbate 20 (20 mcg), sodium chloride (73.1 mcg), D-sucrose (2.74 mg) and Water for Injection, adjusted to pH 5.5 with acetic acid. The product does not contain an anti-microbial preservative.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-S12" id="section-S12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-S12.1" id="section-S12.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD, DME, and RVO. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD, DME, and RVO has yet to be established.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-S12.2" id="section-S12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Increased retinal thickness, assessed by optical coherence tomography (OCT), is associated with nAMD, DME and macular edema following RVO. Leakage of blood and fluid from choroidal neovascularization, assessed by fluorescein angiography, is associated with nAMD. Reductions in CST were observed across all treatment arms throughout the six Phase 3 studies in nAMD, DME, and RVO.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-S12.3" id="section-S12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-" id="section-"></a><p></p>
<p class="First"><span class="Italics">Absorption/Distribution</span></p>
<p>Maximum faricimab plasma concentrations (Cmax) are estimated to occur approximately 2 days post-dose. Mean (±SD) free faricimab (unbound to VEGF-A and Ang-2) plasma Cmax are estimated to be 0.23 (0.07) mcg/mL and 0.22 (0.07) mcg/mL in nAMD and in DME patients, respectively. After repeated intravitreal administrations, mean plasma free faricimab trough concentrations are predicted to be 0.002-0.003 mcg/mL for every 8 weeks (Q8W) dosing and 0.021-0.029 mcg/mL for every 4 weeks (Q4W) dosing. Although not directly measured in the vitreous, no accumulation of faricimab is expected in the vitreous and no accumulation has been observed in plasma when faricimab has been administered as repeat doses in the vitreous.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-" id="section-"></a><p></p>
<p class="First"><span class="Italics">Metabolism/Elimination</span></p>
<p>Metabolism and elimination of faricimab has not been fully characterized. Faricimab is expected to be catabolized in lysosomes to small peptides and amino acids, which may be excreted renally, in a similar manner to the elimination of endogenous IgG. The estimated mean apparent systemic half-life of faricimab is approximately 7.5 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-" id="section-"></a><p></p>
<p class="First"><span class="Italics">Specific Populations</span></p>
<p>The systemic pharmacokinetics of faricimab were not influenced by gender, race, or mild to severe renal impairment (i.e., estimated normalized creatinine clearance by Cockroft-Gault equation: 15 to 89 mL/min/1.73 m<span class="Sup">2</span>). The effect of severe renal impairment or any degree of hepatic impairment on the pharmacokinetics of VABYSMO is unknown. No special dosage modification is required for any of the populations that have been studied (e.g., elderly, gender, race).</p>
<p>Population pharmacokinetic analysis indicated that the pharmacokinetics of faricimab are comparable in nAMD, DME, and RVO patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="88830-5">
<a name="section-S12.6" id="section-S12.6"></a><p></p>
<h2>12.6	Immunogenicity</h2>
<p class="First">The immunogenicity of VABYSMO was evaluated in plasma samples. The immunogenicity data reflect the percentage of patients whose test results were considered positive for antibodies to VABYSMO in immunoassays. The detection of an immune response is highly dependent on the sensitivity and specificity of the assays used, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to VABYSMO with the incidence of antibodies to other products may be misleading.</p>
<p>There is a potential for an immune response in patients treated with VABYSMO. In the nAMD, DME, and RVO studies, the pre-treatment incidence of anti-faricimab antibodies was approximately 0.8 to 1.8%. After initiation of dosing, the incidence of anti-faricimab antibodies was approximately 8% to 10.4% in patients treated with VABYSMO across studies. As with all therapeutic proteins, there is a potential for immunogenicity with VABYSMO.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-S13" id="section-S13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-S13.1" id="section-S13.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity or mutagenicity data are available for VABYSMO injection in animals or humans.</p>
<p>Based on the anti-VEGF and Ang-2 mechanisms of action, treatment with VABYSMO may pose a risk to reproductive capacity <span class="Italics">[see <a href="#section-S8.3a">Females and Males of Reproductive Potential (8.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-S14" id="section-S14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S14.1" id="section-S14.1"></a><p></p>
<h2>14.1	Neovascular (wet) Age-Related Macular Degeneration (nAMD)</h2>
<p class="First">The safety and efficacy of VABYSMO were assessed in two randomized, multi-center, double-masked, active comparator-controlled, 2-year studies (TENAYA – NCT03823287 and LUCERNE – NCT03823300) in patients with nAMD.</p>
<p>A total of 1,329 newly diagnosed, treatment-naive patients were enrolled in these studies, and 664 patients received at least one dose of VABYSMO. Patient ages ranged from 50 to 99 with a mean of 75.9 years. The studies were identically designed two year studies. Patients were randomized in a 1:1 ratio to one of two treatment arms: 1) aflibercept 2 mg administered fixed every 8 weeks (Q8W) after three initial monthly doses; and VABYSMO 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to determine whether to give a 6 mg (0.05 mL of 120 mg/mL solution) dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44; (also referred to as Q16W dosing); 2) Weeks 24, 36 and 48 (also referred to as Q12W dosing); or 3) Weeks 20, 28, 36 and 44 (also referred to as Q8W dosing). However, the utility of these criteria to guide dosing intervals has not been established.</p>
<p>At week 48, after 4 initial monthly doses in the VABYSMO arm, 45% of patients received the  Weeks 28 and 44 dosing, 33% of patients received the Weeks 24, 36 and 48 dosing, and the remaining 22% of patients received dosing every 8 weeks. These percentages are reflective of what happened within the conduct of these trials and indicate that some patients did well on two (2) doses spaced 16 weeks apart, or three (3) doses spaced 12 weeks apart, but the percentages may not be generalizable to a broader nAMD population for a variety of reasons. The inclusion/exclusion criteria limited enrollment to a select subset of treatment naive, newly diagnosed nAMD patients and there is no empirical data that a similar magnitude would be observed if eligibility criteria allowed for broader enrollment. The disease activity criteria, which was instrumental in determining dose frequency, is unvalidated. Stricter criteria would have changed how patients were treated resulting in different percentages of subjects in each dose interval cohort. There was not a similarly dosed aflibercept arm for comparison, which makes the percentages difficult to interpret.</p>
<p>Both studies demonstrated non-inferiority to the comparator control (aflibercept) at the primary endpoint, defined as the mean change from baseline in Best Corrected Visual Acuity (BCVA) when averaged over the week 40, 44, and 48 visits and measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter chart. The primary endpoint analysis was a non- inferiority comparison for the mean change in BCVA between the aflibercept and the VABYSMO arm. The lower bound of the 95% confidence interval for the mean change in BCVA could not be lower than minus 4 letters to declare non-inferiority. In both studies, VABYSMO treated patients had a non-inferior mean change from baseline in BCVA compared to patients treated with aflibercept. Detailed results of both studies are shown in <a href="#section-table2">Table 2</a>, <a href="#section-FIGURE_1">Figure 1</a>, and <a href="#section-FIGURE_2">Figure 2</a> below. The clinical efficacy for the second year of the study has not been reviewed.</p>
<a name="TABLE2"></a><table width="80%">
<caption><span>Table 2: Primary Endpoint Results<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> in the TENAYA and LUCERNE Studies</span></caption>
<col width="20%" align="left" valign="top">
<col width="20%" align="center" valign="top">
<col width="20%" align="center" valign="top">
<col width="20%" align="center" valign="top">
<col width="20%" align="center" valign="top">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2"></th>
<th class="Rrule" align="center" colspan="2">TENAYA</th>
<th class="Rrule" align="center" colspan="2">LUCERNE</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">VABYSMO<br> N = 334</th>
<th class="Rrule" align="center">Aflibercept<br> N = 337</th>
<th class="Rrule" align="center">VABYSMO<br> N = 331</th>
<th class="Rrule" align="center">Aflibercept<br> N = 327</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="5">BCVA: Best Corrected Visual Acuity</td></tr>
<tr><td align="left" colspan="5">ETDRS: Early Treatment Diabetic Retinopathy Study</td></tr>
<tr><td align="left" colspan="5">CI: Confidence Interval</td></tr>
<tr class="Last"><td align="left" colspan="5">LS: Least Square</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Average of weeks 40, 44 and 48</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Mean change in BCVA as measured by ETDRS letter score from baseline <br>(95% CI)</td>
<td class="Rrule" align="center">5.8<br> (4.6, 7.1)</td>
<td class="Rrule" align="center">5.1<br> (3.9, 6.4)</td>
<td class="Rrule" align="center">6.6<br> (5.3, 7.8)</td>
<td class="Rrule" align="center">6.6<br> (5.3, 7.8)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Difference in LS mean <br>(95% CI)</td>
<td class="Rrule" align="center">0.7<br> (-1.1, 2.5)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">0.0<br> (-1.7, 1.8)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><a name="FIGURE_1"></a>Figure 1: Mean Change in Visual Acuity from Baseline to Week 48 in TENAYA</span></p>
<div class="Figure"><img alt="Figure 1" src="faricimab-13.jpg"></div>
<p><span class="Bold"><a name="FIGURE_2"></a>Figure 2: Mean Change in Visual Acuity from Baseline to Week 48 in LUCERNE</span></p>
<div class="Figure"><img alt="Figure 2" src="faricimab-14.jpg"></div>
<p>Treatment effects in evaluable subgroups (e.g., age, gender, race, baseline visual acuity) in each study were consistent with the results in the overall population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S14.2" id="section-S14.2"></a><p></p>
<h2>14.2	Diabetic Macular Edema (DME)</h2>
<p class="First">The safety and efficacy of VABYSMO were assessed in two randomized, multi-center, double-masked, active comparator-controlled 2-year studies (YOSEMITE – NCT03622580 and RHINE – NCT03622593) in patients with DME.</p>
<p>A total of 1,891 diabetic patients were enrolled in the two studies with a total of 1,262 patients treated with at least one dose of VABYSMO. Patient ages ranged from 24 to 91 with a mean of 62.2 years. The overall population included both anti-VEGF naive patients (78%) and patients who had been previously treated with a VEGF inhibitor prior to study participation (22%).</p>
<p>The studies were identically designed two year studies. Patients were randomized in a 1:1:1 ratio to one of three treatment regimens: 1) aflibercept Q8W, patients received fixed aflibercept 2 mg administered every 8 weeks (Q8W) after the first five monthly doses; 2) VABYSMO Q8W, patients received fixed VABYSMO 6 mg administered Q8W after the first six monthly doses; and 3) VABYSMO Variable, patients received VABYSMO 6 mg administered every 4 weeks for at least 4 doses and until the central subfield thickness (CST) of the macula measured by optical coherence tomography was less than approximately 325 microns, then the interval of dosing was modified by up to 4 week interval extensions or reductions of up to 8 week interval increments based on CST and visual acuity disease activity criteria at study drug dosing visits.</p>
<p>After 4 initial monthly doses, the patients in the VABYSMO Variable arm received between a minimum of 1 and a maximum of 21 total injections (median of 7 injections) through Week 96 inclusive. At Week 56, 32% of patients had completed at least one Q12W interval followed by one full Q16W interval. Seventeen percent (17%) of patients were treated on Q8W and/or Q4W dosing intervals through Week 56 (7% only on Q4W). These percentages are reflective of what happened within the conduct of these trials, but the percentages may not be generalizable to a broader DME population.</p>
<p>The inclusion/exclusion criteria limited enrollment to a select subset of DME patients and there is no empirical data that a similar magnitude would be observed if eligibility criteria allowed for broader enrollment. The disease activity criteria, which were instrumental in determining dose frequency, are unvalidated. Different 								 criteria would have changed how patients were treated resulting in different percentages of subjects in each dose interval cohort. There was not a similarly dosed aflibercept arm for comparison which makes the percentages difficult to interpret.</p>
<p>Both studies demonstrated non-inferiority to the comparator control (aflibercept) at the primary endpoint, defined as the mean change from baseline in BCVA at year 1 (average of the Week 48, 52, and 56 visits), measured by the ETDRS Letter Score. The primary endpoint analysis was a non-inferiority comparison for the mean change in BCVA between the aflibercept and VABYSMO arms. The lower bound of the 97.5% confidence interval for the mean change in BCVA could not be lower than minus 4 letters to declare non-inferiority. In both studies, VABYSMO Q8W and VABYSMO Variable treated patients had a non-inferior mean change from baseline in BCVA to the patients treated with aflibercept Q8W at the year 1 primary endpoint. Detailed results of both studies are shown in <a href="#section-table3">Table 3</a>, <a href="#section-FIGURE_3">Figure 3</a>, and <a href="#section-FIGURE_4">Figure 4</a> below.</p>
<a name="TABLE3"></a><table width="100%">
<caption><span>Table 3: Efficacy Results at Year 1<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> and at Year 2<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a> in the YOSEMITE and RHINE Studies</span></caption>
<col width="16%" align="left" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<col width="7%" align="center" valign="top">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="3"></th>
<th class="Rrule" align="center" colspan="6">YOSEMITE</th>
<th class="Rrule" align="center" colspan="6">RHINE</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center" colspan="3">Year 1</th>
<th class="Rrule" align="center" colspan="3">Year 2</th>
<th class="Rrule" align="center" colspan="3">Year 1</th>
<th class="Rrule" align="center" colspan="3">Year 2</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">VABYSMO <br>Q8W<br> N = 315</th>
<th class="Rrule" align="center">VABYSMO <br>Variable<br> N = 313</th>
<th class="Rrule" align="center">Aflibercept <br>Q8W<br> N = 312</th>
<th class="Rrule" align="center">VABYSMO Q8W<br>N = 262</th>
<th class="Rrule" align="center">VABYSMO Variable<br>N = 270</th>
<th class="Rrule" align="center">Aflibercept Q8W<br>N = 259</th>
<th class="Rrule" align="center">VABYSMO<br> Q8W<br> N = 317</th>
<th class="Rrule" align="center">VABYSMO <br>Variable<br> N = 319</th>
<th class="Rrule" align="center">Aflibercept <br>Q8W<br> N = 315</th>
<th class="Rrule" align="center">VABYSMO Q8W<br>N = 259</th>
<th class="Rrule" align="center">VABYSMO Variable<br>N = 282</th>
<th class="Rrule" align="center">Aflibercept Q8W<br>N = 254</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="13">BCVA: Best Corrected Visual Acuity</td></tr>
<tr><td align="left" colspan="13">ETDRS: Early Treatment Diabetic Retinopathy Study</td></tr>
<tr><td align="left" colspan="13">CI: Confidence Interval</td></tr>
<tr class="Last"><td align="left" colspan="13">LS: Least Square</td></tr>
<tr><td colspan="13" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Average of Weeks 48, 52, 56 </dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Average of Weeks 92, 96, 100</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>A non-inferiority margin was not available for year 2</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Mean change in BCVA as measured by ETDRS letter score from baseline <br>(97.5% CI year 1 and 95% CI year 2)</td>
<td class="Rrule" align="center">10.7<br> (9.4, 12.0)</td>
<td class="Rrule" align="center">11.6<br> (10.3, 12.9)</td>
<td class="Rrule" align="center">10.9<br> (9.6, 12.2)</td>
<td class="Rrule" align="center">10.7<br>(9.4, 12.1)</td>
<td class="Rrule" align="center">10.7<br>(9.4, 12.1)</td>
<td class="Rrule" align="center">11.4<br>(10.0, 12.7)</td>
<td class="Rrule" align="center">11.8<br> (10.6, 13.0)</td>
<td class="Rrule" align="center">10.8<br> (9.6, 11.9)</td>
<td class="Rrule" align="center">10.3<br> (9.1, 11.4)</td>
<td class="Rrule" align="center">10.9<br>(9.5, 12.3)</td>
<td class="Rrule" align="center">10.1<br>(8.7, 11.5)</td>
<td class="Rrule" align="center">9.4<br>(7.9, 10.8)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Difference in LS mean <br>(97.5% CI year 1 and 95% CI year 2)</td>
<td class="Rrule" align="center">-0.2<br> (-2.0, 1.6)</td>
<td class="Rrule" align="center">0.7<br> (-1.1, 2.5)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-0.7<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">-0.7<a href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1.5<br> (-0.1, 3.2)</td>
<td class="Rrule" align="center">0.5<br> (-1.1, 2.1)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1.5<a href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.7<a href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><a name="FIGURE_3"></a>Figure 3: Mean Change in Visual Acuity from Baseline to Year 2 (Week 100) in YOSEMITE</span></p>
<div class="Figure"><img alt="Figure 3" src="faricimab-15.jpg"></div>
<p><span class="Bold"><a name="FIGURE_4"></a>Figure 4: Mean Change in Visual Acuity from Baseline to Year 2 (Week 100) in RHINE</span></p>
<div class="Figure"><img alt="Figure 4" src="faricimab-16.jpg"></div>
<p>Treatment effects in the subgroup of patients who were anti-VEGF naive prior to study participation were similar to those observed in the overall population. Treatment effects in evaluable subgroups (e.g., by age, gender, race, baseline HbA1c, baseline visual acuity) in each study were generally consistent with the results in the overall population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S14.3" id="section-S14.3"></a><p></p>
<h2>14.3	Macular Edema Following Retinal Vein Occlusion (RVO) </h2>
<p class="First">The safety and efficacy of VABYSMO were assessed in two randomized, multicenter, double-masked, studies (BALATON – NCT04740905 in patients with macular edema following branch retinal vein occlusion, and COMINO – NCT04740931 in patients with macular edema following central retinal vein occlusion/hemiretinal vein occlusion). Active comparator-controlled data are available through month 6.</p>
<p>A total of 1,282 newly diagnosed, treatment-naive patients were enrolled in these studies, of which 641 patients received at least one dose of VABYSMO through 6 months. Patient ages ranged from 28 to 93 with a mean of 64 years, and 22 to 100 with a mean of 65 years in BALATON and COMINO, respectively.</p>
<p>In both studies, patients were randomized in a 1:1 ratio to either 6 mg VABYSMO administered every 4 weeks, or the control arm receiving aflibercept 2 mg injections every 4 weeks for a total of 6 injections.</p>
<p>In both studies, the VABYSMO 6 mg Q4W arm demonstrated non-inferiority to the comparator control (aflibercept) arm for the primary endpoint, which was defined as the change from baseline in BCVA at week 24, measured by the ETDRS Letter Score. The primary endpoint analysis was a non-inferiority comparison for the mean change in BCVA between the aflibercept and VABYSMO arms, where the lower bound of the 95% confidence interval for the mean change in BCVA could not be lower than minus 4 letters to declare non-inferiority.</p>
<p>Detailed results for both BALATON and COMINO studies are shown in <a href="#table4">Table 4</a>, <a href="#section-fig5">Figure 5</a>, and <a href="#section-fig6">Figure 6</a> below.</p>
<a name="table4"></a><table width="90%">
<caption><span>Table 4: Primary Endpoint Results at Week 24 in the BALATON and COMINO Studies </span></caption>
<col width="24%" align="left" valign="top">
<col width="19%" align="center" valign="top">
<col width="19%" align="center" valign="top">
<col width="19%" align="center" valign="top">
<col width="19%" align="center" valign="top">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2"></th>
<th class="Rrule" align="center" colspan="2">BALATON</th>
<th class="Rrule" align="center" colspan="2">COMINO</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">VABYSMO<br>N = 276</th>
<th class="Rrule" align="center">Aflibercept<br>N = 277</th>
<th class="Rrule" align="center">VABYSMO<br>N = 366</th>
<th class="Rrule" align="center">Aflibercept<br>N = 363</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="5">BCVA: Best Corrected Visual Acuity</td></tr>
<tr><td align="left" colspan="5">ETDRS: Early Treatment Diabetic Retinopathy Study</td></tr>
<tr><td align="left" colspan="5">CI: Confidence Interval</td></tr>
<tr class="Last"><td align="left" colspan="5">LS: Least Square</td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Mean change in BCVA as measured by ETDRS letter score from baseline (95% CI)</td>
<td class="Rrule" align="center">16.9<br>(15.7, 18.1)</td>
<td class="Rrule" align="center">17.5<br>(16.3, 18.6)</td>
<td class="Rrule" align="center">16.9<br>(15.4, 18.3)</td>
<td class="Rrule" align="center">17.3<br>(15.9, 18.8)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Difference in LS mean (95% CI)</td>
<td class="Rrule" align="center">-0.6<br>(-2.2, 1.1)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-0.4<br>(-2.5, 1.6)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p><a name="fig5"></a><span class="Bold">Figure 5: Mean Change in Visual Acuity from Baseline to Week 24 in BALATON</span></p>
<p><img alt="Figure 5" src="faricimab-17.jpg"></p>
<p><a name="fig6"></a><span class="Bold">Figure 6: Mean Change in Visual Acuity from Baseline to Week 24 in COMINO </span></p>
<p><img alt="Figure 6" src="faricimab-18.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-S16" id="section-S16"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-S16.1" id="section-S16.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<p class="First">VABYSMO (faricimab-svoa) injection is supplied as a clear to opalescent, colorless to brownish-yellow 120 mg/mL solution in a single-dose glass vial. Each glass vial contains an overfill amount to allow for administration of a single 0.05 mL dose of solution containing 6 mg of VABYSMO.  Each VABYSMO carton (NDC 50242-096-01) contains one glass vial and one sterile 5-micron blunt transfer filter needle (18-gauge × 1½ inch, 1.2 mm × 40 mm).</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-S16.2" id="section-S16.2"></a><p></p>
<h2>16.2	Storage and Handling</h2>
<p class="First">Store VABYSMO in the refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze. Do not shake. Keep the vial in the original carton to protect from light.</p>
<p>Prior to use, the unopened glass vial of VABYSMO may be kept at room temperature, 20°C to 25°C (68°F to 77°F), for up to 24 hours. Ensure that the injection is given immediately after preparation of the dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-S17" id="section-S17"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients that in the days following VABYSMO administration, patients are at risk of developing endophthalmitis, retinal detachment, intraocular inflammation and retinal vasculitis with or without retinal vascular occlusion. If the eye becomes red, sensitive to light, painful, or develops a change in vision, advise the patient to seek immediate care from an ophthalmologist <span class="Italics">[see <a href="#section-S5">Warnings and Precautions (5)</a>]</span>.</p>
<p>Patients may experience temporary visual disturbances after an intravitreal injection with VABYSMO and the associated eye examinations <span class="Italics">[see <a href="#section-S6">Adverse Reactions (6)</a>]</span>. Advise patients not to drive or use machinery until visual function has recovered sufficiently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-" id="section-"></a><p></p>
<p class="First">VABYSMO<span class="Sup">®</span> [faricimab-svoa]<br>Manufactured by:<br><span class="Bold">Genentech, Inc</span>.<br> A Member of the Roche Group<br>1 DNA Way<br>South San Francisco, CA 94080-4990<br>U.S. License No.: 1048</p>
<p><span class="Italics">VABYSMO</span> is a trademark of Genentech, Inc.<br><span class="Sup">©</span>2023 Genentech, Inc.</p>
<p>Representative sample of labeling (see the <a href="#section-S16">HOW SUPPLIED</a> section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-" id="section-"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 6 mg Vial Carton</h1>
<p class="First">Vabysmo™<br> (faricimab-svoa)<br> Injection</p>
<p>NDC 50242-096-01</p>
<p>6 mg (0.05 mL of 120 mg/mL solution)</p>
<p>For Intravitreal Injection. Single-Dose Vial.<br> Discard Unused Portion.</p>
<p>1 single-dose vial<br> 1 transfer filter needle</p>
<p>Rx only<br> Genentech</p>
<p>10239448</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 6 mg Vial Carton" src="faricimab-19.jpg"></div>
</div>
</div></div>
<p><div class="EffectiveDate">Revised: 10/2023<div class="DocumentMetadata">
<div>Document Id: 6815251d-7f8d-4b04-8fc5-b1ec85a617ca</div>
<div>Set id: 04cc9ef7-c02a-4e92-a655-0062674e8487</div>
<div>Version: 6</div>
<div>Effective Time: 20231031</div>
</div>
</div> </p>
<div class="clear"></div>
<script type="text/javascript" src="../assets/js/jScrollTouch.js"></script><script type="application/javascript" src="../assets/js/search.js"></script><script type="text/javascript" src="../assets/js/jquery.scrollTo-1.4.2-min.js"></script><script type="text/javascript" src="../assets/js/omniture.js"></script>
</div></body>
</html>
